Replies to post #187 on Equity Field Notes from temporal sources

[DanWebzster]

RHHBY : The world's biggest Pharma & the world's biggest diagnostic company has been dropping for most of 2018, despite increasing full year guidance.

Yield is ~4%

Pessimism revolves around the upcoming wave of patent expiries for its big 3 products: Rituxin, Avistin & Herceptin.

Plans for growth revolve around 3 new products:

1. Tencentriq has been a disappointment so far; but, it is being studied alone and in combination in 8 Ph3 studies

2. Ocrevus is the only drug approved for PPMS. It is licensed from BIIB

3. Hemlibra has been approved for a subset of Hemophilia A and label expansion is being sought

Ex-div date is once per year. In 2018, Ex-div was 3/15

I would only trade this with a strong bottoming pattern.